Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives $24.00 Average PT from Brokerages

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have received an average recommendation of “Hold” from the five analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $24.00.

Several research firms recently weighed in on ARTL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artelo Biosciences in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Artelo Biosciences to a “strong sell” rating in a report on Saturday, August 9th. D. Boral Capital reaffirmed a “hold” rating on shares of Artelo Biosciences in a report on Monday, September 8th. Finally, D Boral Capital downgraded shares of Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th.

Artelo Biosciences Stock Performance

Shares of ARTL opened at $3.37 on Thursday. Artelo Biosciences has a 1 year low of $3.15 and a 1 year high of $28.60. The company has a market cap of $2.36 million, a price-to-earnings ratio of -0.18 and a beta of 1.41. The firm has a fifty day moving average of $5.77 and a 200-day moving average of $7.80.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($5.61) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($5.48). Analysts predict that Artelo Biosciences will post -2.62 EPS for the current year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.